Direct Impact

Concepts for which Luigi Gugliotta has direct influence:

idiopathic hypereosinophilic
eosinophilic leukemia
conditioning prior
haematological malignancies
haematopoietic stem
trial evaluate
safety treosulfan

Prominent publications by Luigi Gugliotta

KOL-Index: 31 Abstract Abstract 787 Background: Many studies support the value of PCR-based MRD detection using the bcl-2-IgH translocation as an outcome predictor in FL but some failed to confirm this observation. Concerns have been raised particularly for programs which are highly Rituximab (Rtx) intensive (with or without maintenance) and non-ASCT-based. The ...
Known for
Honoraria Roche | Pts Arm | Timepoints Fnd | Rtx Maintenance
KOL-Index: 28 Abstract Induction treatment of acute myeloid leukemia (AML) is conventionally based on regimens containing cytarabine (Ara-C), one anthracycline and, sometimes, a third drug, such as etoposide. Primary P-glycoprotein (Pgp) overexpression is the most important mechanism of multidrug resistance (MDR) in AML cells and it is almost always associated with less response to treatment. To ...
Known for
Ara | Induction Flai | Mdrve Cells | Pgp Expression
KOL-Index: 10 Abstract Abstract 1973 Background. Hematological and extra-hematological adverse events associated to Hydroxyurea (HU) treatment in patients with chronic myeloproliferative neoplasms (MPN) are object of particular interest in the Ph-negative MPN since they can significantly limit the HU use. Objective. To evaluate ...
Known for
28 Fever | Chronic Myeloproliferative Neoplasms | Et-Ehaes | 38 Hyperpigmentation
KOL-Index: 9 Abstract Abstract 2415 Poster Board II-392 We previously reported that in adults with primary immune thrombocytopenia (ITP) the addition of four weekly administrations of rituximab 375 mg/m2 to a single course of dexamethasone (40 mg daily for four days) improves the rate of sustained response (SR, i.e. platelet count 3 50 × 109/L at month 6 from the beginning of ...
Known for
Primary Immune | Fisher Test | Therapy Arm | Tfs
KOL-Index: 5 BACKGROUND: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the ...
Known for
Long-Term Progression-Free Survival | 40 | Hsct | 60
KOL-Index: 5 Abstract We studied 141 patients with HES, of which 55 primary HES (39%) defined as a peripheral blood eosinophilia greater than 1,500 cells/μL for longer than 6 months, absence of other apparent aetiologies for eosinophilia and symptoms of organ involvement. All patients were studied by molecular analysis for PDGFRB-TEL, FGFR1-BCR and BCR-ABL transcripts, frequently associated with ...
Known for
Μl | Bcr-Abl Transcripts | 23 | Pts Months
KOL-Index: 3 Abstract Introduction. Previous uncontrolled studies have highlighted the activity of rituximab in patients with idiopathic thrombocytopenic purpura (ITP) relapsed or refractory to standard treatments. To better address this effect, a prospective randomized (1:1), multicenter, phase III study comparing treatment with dexamethasone alone (arm A) vs dexamethasone plus rituximab (arm ...
Known for
Arm Arm | 109 | Salvage Therapy | Comparing Rituximab
KOL-Index: 2 The purpose of this study is to assess the clinical anti-proliferative activity of STI571 (Glivec®, Novartis, Pharma) in patients with HES defined as:Idiopathic Hypereosinophilic Syndrome (secondary HES), defined as a peripheral blood eosinophilia greater than 1,500 cells/µL for longer than 6 months, absence of other apparent aetiologies for eosinophilia and with or without signs and ...
Known for
Myeloproliferative Disorder | Symptoms Organ | Pharma Defined | Glivec Novartis
KOL-Index: 2 This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in patients with haematological malignancies.The aim is to demonstrate a clinical benefit compared with historical data on intravenous busulfan ...
Known for
Prior Allogeneic | Phase Trial | Combination Regimen | Transplantation Haematological

Hematology, Hosp.S.Maria Nuova, Reggio Emilia, Italy

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172